ArticleInternational journal of molecular sciences2025

Long-Term Real-World Effectiveness of Dupilumab vs. Upadacitinib in Early Treatment Responders with Atopic Dermatitis: Results from Central European Health Fund Registry.

Katarzyna Waligóra-Dziwak et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.